NASDAQ:BCLI Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free BCLI Stock Alerts $0.56 -0.04 (-6.61%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.49▼$0.6050-Day Range$0.28▼$0.6652-Week Range$0.13▼$3.46Volume647,340 shsAverage Volume962,356 shsMarket Capitalization$27.66 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Brainstorm Cell Therapeutics alerts: Email Address Brainstorm Cell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,670.9% Upside$10.00 Price TargetShort InterestHealthy1.74% of Shares Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.71Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.70) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.35 out of 5 starsMedical Sector145th out of 938 stocksBiological Products, Except Diagnostic Industry19th out of 148 stocks 3.0 Analyst's Opinion Consensus RatingBrainstorm Cell Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Brainstorm Cell Therapeutics has a forecasted upside of 1,670.9% from its current price of $0.56.Amount of Analyst CoverageBrainstorm Cell Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.74% of the outstanding shares of Brainstorm Cell Therapeutics have been sold short.Short Interest Ratio / Days to CoverBrainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainstorm Cell Therapeutics has recently decreased by 20.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBrainstorm Cell Therapeutics does not currently pay a dividend.Dividend GrowthBrainstorm Cell Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBrainstorm Cell Therapeutics has received a 76.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for the nervous system", "Preclinical research services for physical health", and "Preclinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Brainstorm Cell Therapeutics is -0.66. Previous Next 3.7 News and Social Media Coverage News SentimentBrainstorm Cell Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Brainstorm Cell Therapeutics this week, compared to 2 articles on an average week.Search Interest12 people have searched for BCLI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows9 people have added Brainstorm Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.45% of the stock of Brainstorm Cell Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($0.70) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainstorm Cell Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainstorm Cell Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Read More BCLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCLI Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Crosses Above 200 Day Moving Average of $0.33March 27, 2024 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Sell Rating from Analysts at StockNews.comMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 25, 2024 | msn.comWhy Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day SessionMarch 19, 2024 | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.comMarch 6, 2024 | finance.yahoo.comBCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…February 29, 2024 | investing.comBrainStorm details Phase 3b trial for ALS treatment NurOwnFebruary 27, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific ConferenceMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!February 27, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific ConferenceFebruary 25, 2024 | finance.yahoo.comBCLI Mar 2024 1.500 callFebruary 23, 2024 | marketwatch.comBrainStorm Cell Therapeutics Shares Rise 7.2% on NurOwn Study Request to FDAFebruary 23, 2024 | msn.comBrainStorm submits SPA request to FDA for Phase 3 study designFebruary 23, 2024 | prnewswire.comBrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALSFebruary 16, 2024 | wsj.comBrainstorm Cell Therapeutics Inc.February 13, 2024 | uk.investing.comBrainstorm Cell Therapeutics Inc (BCLI)February 13, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics to Present at European Life Sciences CEO ForumFebruary 1, 2024 | finance.yahoo.comBrainstorm Cell Therapeutics Inc. (BCLI)January 14, 2024 | seekingalpha.comBCLI Brainstorm Cell Therapeutics Inc.January 1, 2024 | businesswire.comBCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before ...December 26, 2023 | marketwatch.comBrainstorm Cell Therapeutics Shares Rise 11% on Patent ApprovalsDecember 26, 2023 | msn.comBrainStorm Cell Therapeutics spikes on patent winsDecember 26, 2023 | finance.yahoo.comBrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder TreatmentsDecember 22, 2023 | barrons.comINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming DeadlineDecember 20, 2023 | finanznachrichten.deBrainStorm Cell Therapeutics Inc.: BrainStorm Issues 2023 Letter to ShareholdersDecember 20, 2023 | finance.yahoo.comBrainStorm Issues 2023 Letter to ShareholdersDecember 17, 2023 | morningstar.comBCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud LawsuitSee More Headlines Receive BCLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today3/28/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BCLI CUSIPN/A CIK1137883 Webwww.brainstorm-cell.com Phone(201) 488-0460FaxN/AEmployees42Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+1,670.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,280,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-310.78% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-7.06Miscellaneous Outstanding Shares48,980,000Free Float46,312,000Market Cap$27.66 million OptionableOptionable Beta0.22 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Chaim Lebovits (Age 53)President & CEO Comp: $990.42kDr. Stacy R. Lindborg Ph.D. (Age 54)Co-Chief Executive Officer Comp: $708.39kDr. Irit Arbel DSc (Age 64)Ph.D., Co-Founder & Independent Vice Chair of the Board Mr. Uri Yablonka (Age 47)Executive VP, Chief Business Officer, Secretary & Director Ms. Alla Patlis CPA (Age 37)M.B.A., Controller & Interim CFO Comp: $80kDr. Daniel Offen Ph.D.Chief Scientific AdvisorMs. Mary Kay TurnerSenior Vice President of Patient Advocacy & Government AffairsDr. Ibrahim Dagher M.D. (Age 55)Executive VP & Chief Development Officer More ExecutivesKey CompetitorsMiNK TherapeuticsNASDAQ:INKTCortexymeNASDAQ:CRTXGamida CellNASDAQ:GMDASurrozenNASDAQ:SRZNJATT AcquisitionNYSE:JATTView All CompetitorsInsiders & InstitutionsBarclays PLCBought 23,200 shares on 2/15/2024Ownership: 0.000%Citadel Advisors LLCSold 77,900 shares on 2/15/2024Ownership: 0.000%ADAR1 Capital Management LLCBought 100,700 shares on 2/14/2024Ownership: 0.000%Stacy LindborgBought 11,500 shares on 9/1/2023Total: $20,355.00 ($1.77/share)View All Insider TransactionsView All Institutional Transactions BCLI Stock Analysis - Frequently Asked Questions Should I buy or sell Brainstorm Cell Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares. View BCLI analyst ratings or view top-rated stocks. What is Brainstorm Cell Therapeutics' stock price target for 2024? 1 brokerages have issued twelve-month price targets for Brainstorm Cell Therapeutics' shares. Their BCLI share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 1,670.9% from the stock's current price. View analysts price targets for BCLI or view top-rated stocks among Wall Street analysts. How have BCLI shares performed in 2024? Brainstorm Cell Therapeutics' stock was trading at $0.2730 on January 1st, 2024. Since then, BCLI shares have increased by 106.8% and is now trading at $0.5647. View the best growth stocks for 2024 here. Are investors shorting Brainstorm Cell Therapeutics? Brainstorm Cell Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 850,300 shares, a decline of 20.5% from the February 29th total of 1,070,000 shares. Based on an average daily trading volume, of 1,430,000 shares, the days-to-cover ratio is currently 0.6 days. View Brainstorm Cell Therapeutics' Short Interest. When is Brainstorm Cell Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our BCLI earnings forecast. How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) released its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). During the same period in the previous year, the firm earned ($0.19) earnings per share. What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP). Who are Brainstorm Cell Therapeutics' major shareholders? Brainstorm Cell Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ADAR1 Capital Management LLC (0.00%), Barclays PLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCLI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.